Abstracts tagged "spondyloarthritis"

Abstract Number: 2022 • ACR Convergence 2020
Effects of Anti-TNF-therapy on Osteoblastic Activity in Ankylosing Spondylitis – Results from a Prospective Study Using PET-MRI of SIJ and Spine
Xenofon Baraliakos¹, Styliani Tsiami², Christoph Rischpler³, Nils-Martin Bruckmann⁴, Wolfgang Fendler³, Julian Kirchner⁵, Ken Herrmann³, Lino Morris Sawicki⁵ and Juergen Braun⁶, ¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³Department of Nuclear Medicine, University Essen-Duisburg, Essen, Germany, ⁴Department of Radiology, University Duesseldorf, Düsseldorf, Germany, ⁵Department of Radiology, University Duesseldorf, Duesseldorf, Germany, ⁶Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, 44649 Herne, Germany
Background/Purpose: The clinical efficacy of TNFi in patients with axSpA is well established but its effect on new bone formation is still unclear. Positron emission…
Abstract Number: 0341 • ACR Convergence 2020
Metabolomics Profiling of Human Serum for Discovering Biomarkers to Diagnose Psoriatic Arthritis and Ankylosing Spondylitis with High Specificity
Wei Han¹, Xiaohang Wang¹, Liang Li¹, Stephanie Wichuk², Edna Hutchings³, Rana Dadashova³, Joel Paschke³ and Walter Maksymowych², ¹Department of Chemistry, University of Alberta, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³CARE Arthritis, Edmonton, AB, Canada
Background/Purpose: In this work, we applied a high-performance chemical isotope labeling (CIL) LC-MS platform to search for biomarker candidates of PsA and AS in human…
Abstract Number: 0875 • ACR Convergence 2020
Secukinumab Provides Sustained Improvements in Subgroup Analyses of Joint Tenderness and Swelling in Patients with Psoriatic Arthritis: 5‑Year Results from the Phase 3 FUTURE 2 Study
Iain McInnes¹, Hector Chinoy², Darren Asquith³, Abigail White³ and Corine Gaillez⁴, ¹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²The University of Manchester, Manchester, United Kingdom, ³Novartis Pharmaceuticals UK Ltd., London, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human monoclonal antibody that neutralizes interleukin‑17A, has shown long-term efficacy and tolerability in patients with psoriatic arthritis (PsA) in FUTURE 2.…
Abstract Number: 1303 • ACR Convergence 2020
Performance of Three Referral Algorithms for Diagnosing Axial Spondyloarthritis: Results from the Screening in Axial Spondyloarthritis for Psoriasis, Iritis, and Colitis Cohort
Ulrich Weber¹, Raj Carmona², James Yeung³, Jon Chan⁴, Liam Martin⁵, Ariel Masetto⁶, Stephanie Keeling⁷, Olga Ziouzina⁵, Sherry Rohekar⁸, Rana Dadashova⁹, Joel Paschke⁹, Amanda Carapellucci⁹, Robert G Lambert¹⁰, Walter Maksymowych⁷ and Sibel Aydin¹¹, ¹University of South Denmark, Odense, Denmark, ²St. Joseph's Healthcare, Hamilton, ON, Canada, ³James Yeung Rheumatology, Vancouver, BC, Canada, ⁴Artus Health Clinic, Vancouver, BC, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶University of Sherbrooke, Sherbrooke, QC, Canada, ⁷University of Alberta, Edmonton, AB, Canada, ⁸Lawson Health Research Institute, London, ON, Canada, ⁹CARE Arthritis, Edmonton, AB, Canada, ¹⁰University of Alberta and CARE Arthritis, Edmonton, AB, Canada, ¹¹University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA; The Ottawa Hospital Research Institute, Ottawa, ON, CANADA, Ottawa, ON, Canada
Background/Purpose: Patients presenting with back pain and psoriasis, acute anterior uveitis (AAU), or inflammatory bowel disease (IBD), represent a high-risk population for the presence of…
Abstract Number: 1338 • ACR Convergence 2020
Identification of Muscle Associated Key Genes to Support Axial Spondyloarthritis Diagnosis by Transcriptomic Approach, the MyoSpA Study
Atlas Mashayekhi Sardoo¹, Daniel Sobral², Lucia Domingues³, Santiago Rodrigues-Manica⁴, Rita Pinheiro Torres⁴, Agna Neto⁵, Ana Filipa Fernandes⁶, Patricia Alves⁷, Julia Costa⁶, Ana Rita Grosso², Celso Cunha⁸, Jaime Branco⁹ and Fernando M Pimentel-Santos⁴, ¹3. CEDOC, NOVA Medical School, Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal, Lisbon, Portugal, ²Faculty of Science and Technology, Universidade Nova de Lisboa, Caparica, Portugal, ³NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal, ⁴CHLO, Hospital Egas Moniz, Lisbon, Portugal, ⁵1. Rheumatology Department, Hospital Central do Funchal, Madeira, Portugal. 2. Hospital de Egas Moniz, CHLO, Lisbon, Portugal. 3. CEDOC, NOVA Medical School, Lisbon, Portugal, Lisbon, Portugal, ⁶ITQB-NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Oeiras, Portugal, ⁷IBET - Institute of Experimental Biology and Technology, Oeiras, Portugal, ⁸Instituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de Lisboa, Lisbon, Portugal, ⁹2. Hospital de Egas Moniz, CHLO, Lisbon, Portugal. 3. CEDOC, NOVA Medical School, Lisbon, Portugal, Lisbon, Portugal
Background/Purpose: Early diagnosis of axial Spondyloarthritis (axSpA) represents a major clinical challenge nowadays. Increasing evidence has determined that early diagnosis, prompt treatment initiation and early…
Abstract Number: 1519 • ACR Convergence 2020
Interleukin-17D, a Cytokine Derived from Stromal Cells, Attenuates Joint Inflammation
Sijia Chen¹, Catherine Manning², Melissa van Tok³, Yukiko Maeda⁴, Daniel Montoro⁵, Jung-Min Kim⁶, Jeroen den Dunnen³, Nataliya Yeremenko³, Jae-Hyuck Shim⁴, Dominique Baeten⁷ and Ellen Gravallese⁸, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women’s Hospital, Boston, ³Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁴University of Massachusetts Medical School, worcester, MA, ⁵Broad Institute of Massachusetts Institute of Technology and Harvard, Boston, ⁶University of Massachusetts Medical School, Worcester, ⁷UCB Pharma / Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Brigham and Women's Hospital, Boston, MA
Background/Purpose: Interleukin(IL)-17D is a little recognized member of the IL-17 family of cytokines. While the activities of IL-17A and IL-17F in the pathogenesis of spondyloarthritis…
Abstract Number: 1866 • ACR Convergence 2020
Patient-reported Impact of Axial Spondyloarthritis on Working Life. Results from the Spanish Atlas 2017
Marco Garrido-Cumbrera¹, Eduardo Collantes-Estévez², Victoria Navarro-Compán³, Pedro Zarco⁴, Carlos Sastre⁵, Sergio Sanz-Gomez⁶, José Correa-Fernández⁷ and Jordi Gratacós⁸, ¹Health & Territory Research (HTR), Universidad de Sevilla / Spanish Federation of Spondyloarthritis Associations, Sevilla, Spain, ²Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ³Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ⁴Novartis Farmacéutica Spain, Alcorcon, Madrid, Spain, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Health & Territory Research, Seville, Spain, ⁷Health & Territory Research (HTR), Universidad de Sevilla, Sevilla, Spain, ⁸University Hospital Parc Tauli Sabadell, Barcelona, Spain
Background/Purpose: Axial spondyloarthritis (axSpA) impacts negatively on multiple dimensions of patient’s life, including their working life. The present study aims to evaluate working status, work-related…
Abstract Number: 1896 • ACR Convergence 2020
No Relationship Between Lumbar Bone Mineral Density and Syndesmophyte Formation at the Same Level – A Multilevel Analysis in Patients with Radiographic Axial Spondyloarthritis
Mary Lucy Marques¹, Sofia Ramiro², Pedro M Machado³, Désirée van der Heijde⁴ and Floris van Gaalen⁵, ¹Leiden University Medical Center, Coimbra, Portugal, ²Leiden University Medical Center, Bunde, Netherlands, ³University College London, London, United Kingdom, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Leiden University Medical Center (LUMC), Leiden, Netherlands
Background/Purpose: In radiographic axial spondyloarthritis (r-axSpA) it has been hypothesized that inflammation-driven bone loss triggers bone repair but at anatomically distinct sites of the same…
Abstract Number: 2028 • ACR Convergence 2020
Predictors of Maintaining Inactive Disease After Etanercept Withdrawal, and Regaining Inactive Disease Status After Flare and Retreatment, in Adults with Non-radiographic Axial Spondyloarthritis: Results from RE-EMBARK
Filip Van den Bosch¹, James Cheng-Chung Wei², Francisco Blanco³, Pamela Selema⁴, Daniela Graham⁵, Edmund Arthur⁶, Vassilis Tsekouras⁷, Bonnie Vlahos⁴, Chuanbo Zang⁴, Atul Deodhar⁸ and Peter Nash⁹, ¹Ghent University Hospital, Ghent, Belgium, ²Chung Shan Medical University Hospital, Taichung, Taiwan (Republic of China), ³INIBIC-Complejo Hospitalario Universitario A Coruña, A Coruna, Spain, ⁴Pfizer, Collegeville, PA, ⁵Pfizer, Groton, PA, ⁶Pfizer, Peapack, NJ, ⁷Pfizer, Nicosia, Cyprus, ⁸Oregon Health & Science University, Portland, OR, ⁹School of Medicine Griffith University, Brisbane, Queensland, Australia
Background/Purpose: RE-EMBARK was a phase 4, multicenter, open-label, 3-period study that evaluated etanercept (ETN) withdrawal and retreatment in adult patients with non-radiographic axial spondyloarthritis (nr-axSpA)…
Abstract Number: 0348 • ACR Convergence 2020
Biologics History and Sex Are Linked to Golimumab Discontinuation in Axial Spondyloarthritis: A Sub-Analysis of the Post-Registration GO-Practice Study
Philippe Bertin¹, Philippe Goupille², Florence Tubach³, Eric Lespessailles⁴, Naoual Harid⁵, Saannya Sequeira⁶, Jean-Marie Fayette⁶, Bruno Fautrel⁷ and Rene-Marc Flipo⁸, ¹Limoges University Hospital, Limoges, France, ²CHU Tours, department of rheumatology, Tours, France, ³Pierre Louis Institute of Epidemiology and Public Health, INSERM 1136, Sorbonne University and Centre of Pharmacoepidemiology, Pitié Salpêtrière Hospital, APHP.Sorbonne University, Paris, Ile-de-France, France, ⁴Regional Hospital and University of Orleans, Orléans, France, ⁵MSD France Puteaux, Puteaux, Ile-de-France, France, ⁶ClinSearch, Malakoff, Ile-de-France, France, ⁷Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ⁸Lille University Hospital, Lille, France
Background/Purpose: Golimumab (GLM) is the latest anti-TNFα to be indicated for treating rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). The post-registration GO-PRACTICE…
Abstract Number: 0876 • ACR Convergence 2020
Gender Differences in Baseline Clinical Characteristics Among Patients with Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis: Data from 3 Randomized Ixekizumab Controlled Trials
Marina Magrey¹, Kurt de Vlam², Rebecca Bolce³, Soyi Liu-Leage⁴, Danting Zhu⁴, Theresa Hunter³, David Sandoval³ and Irene van der Horst-Bruinsma⁵, ¹Case Western Reserve University School of Medicine, Cleveland, OH, ²Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium, ³Eli Lilly and Company, Indianapolis, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Department of Rheumatology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Ixekizumab (IXE), an anti-interleukin-17A monoclonal antibody, has demonstrated superior efficacy to placebo in the treatment of patients with axial spondyloarthritis (axSpA) (Dougados M et…
Abstract Number: 1305 • ACR Convergence 2020
Is the Occurrence of Acute Anterior Uveitis Linked Primarily to Ankylosing Spondylitis (AS) or to HLA-B27? Results of a 35-Year Follow-Up Family Study of a Swiss Cohort of Patients with AS
Sjef van der Linden¹, Peter Villiger², Zhixiu Li³, Matthew Brown⁴, Heinz Baumberger⁵, Hermine Zandwijk⁶ and Muhammad Khan⁷, ¹Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, ²Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ³Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, ⁴Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ⁵Retired, Flims, Tajikistan, ⁶Retired, Mortroux, Belgium, ⁷Case Western Reserve University, Cleveland OH, Westlake, OH
Background/Purpose: Approximately 30% of HLA-B27(+) patients with ankylosing spondylitis (AS) have one or more episodes of acute anterior uveitis (AAU), a condition that is also…
Abstract Number: 1340 • ACR Convergence 2020
Secukinumab Improves Pain, Morning Stiffness, Fatigue and Physical Function in Tumor Necrosis Factor Inhibitor-Naïve Patients with Non-Radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study
Helena Marzo-Ortega¹, Atul Deodhar², Ricardo Blanco³, Hideto Kameda⁴, Alan Kivitz⁵, Denis Poddubnyy⁶, Marina Magrey⁷, Jianyuan Wang⁸, Sibylle Haemmerle⁸, Abhijit Shete⁸ and Juergen Braun⁹, ¹The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ²Oregon Health & Science University, Portland, OR, ³Hospital University Marqués de Valdecilla, Santander, Spain, ⁴Toho University, Tokyo, Japan, ⁵Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ⁶Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁷Case Western Reserve University School of Medicine, Cleveland, OH, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Rheumazentrum Ruhrgebiet and Ruhr-University, 44649 Herne, Germany
Background/Purpose: Patients with non-radiographic axial spondyloarthritis (nr-axSpA) suffer from comparable disease burden to patients with ankylosing spondylitis/radiographic axSpA (AS/r-axSpA), including inflammatory back pain, morning stiffness,…
Abstract Number: 1535 • ACR Convergence 2020
Frequency and Anatomic Distribution of Magnetic Resonance Imaging Lesions in the Sacro-iliac Joints of Healthy Subjects and Patients with Spondyloarthritis
Sophie Hecquet¹, Jean-Philippe Lustig², Frank Verhoeven¹, Mickaël Chouk¹, Sébastien Aubry², Daniel Wendling³ and Clement Prati¹, ¹Rheumatology, University Teaching Hospital, Besançon, France, ²Radiology, University Teaching Hospital, Besançon, France, ³CHU Besançon, department of rheumatology, Besancon, France
Background/Purpose: Lesions detected by magnetic resonance imaging (MRI) of the sacroiliac joints are critical to the diagnosis of non-radiographic axial spondyloarthritis. However, some lesions, such…
Abstract Number: 1867 • ACR Convergence 2020
Two-Year Diagnostic Consistency in Patients with Chronic Back Pain Suspected of Axial Spondyloarthritis in Protocolised Follow-up: Data from the Spondyloarthritis Caught Early Cohort
Anne Boel¹, Miranda van Lunteren², Karen Fagerli³, Ulf Lindström⁴, Roberta Ramonda⁵, Marleen van de Sande⁶, Désirée van der Heijde⁷ and Floris van Gaalen⁸, ¹Leiden University Medical Centre, Hooge Zwaluwe, Netherlands, ²Leiden University Medical Centre, Weesp, Netherlands, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of Rheumatology and inflammation research, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, ⁵University of Padova, Padova, Italy, ⁶Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Leiden University Medical Center (LUMC), Leiden, Netherlands
Background/Purpose: A diagnosis of (early) axial spondyloarthritis (axSpA) is based on pattern recognition, which can be challenging and may change over time. The aim of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].